1471 related articles for article (PubMed ID: 9002371)
1. Malaria vaccine.
Khurana SK; Talib VH
Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
[TBL] [Abstract][Full Text] [Related]
2. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.
Høgh B
Scand J Infect Dis Suppl; 1996; 102():1-53. PubMed ID: 9060051
[TBL] [Abstract][Full Text] [Related]
3. The development of malaria vaccines: SPf66--what next?
Tanner M; Alonso PL
Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
[TBL] [Abstract][Full Text] [Related]
4. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
[TBL] [Abstract][Full Text] [Related]
5. [Vaccination against malaria. Disappointments and hopes].
Ambroise-Thomas P
Bull Acad Natl Med; 1997 Nov; 181(8):1637-48; discussion 1648-50. PubMed ID: 9554123
[TBL] [Abstract][Full Text] [Related]
6. Asexual blood-stage malaria vaccine development: facing the challenges.
Genton B; Reed ZH
Curr Opin Infect Dis; 2007 Oct; 20(5):467-75. PubMed ID: 17762779
[TBL] [Abstract][Full Text] [Related]
7. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
[TBL] [Abstract][Full Text] [Related]
8. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
Patarroyo ME; Patarroyo MA
Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
[TBL] [Abstract][Full Text] [Related]
9. Potential vaccine antigens of the asexual blood-stages of Plasmodium falciparum.
Anders RF; Brown GV; Coppel RL; Stahl HD; Bianco AE; Favaloro JM; Crewther PE; Culvenor JG; Kemp DJ
Dev Biol Stand; 1985; 62():81-9. PubMed ID: 2422079
[TBL] [Abstract][Full Text] [Related]
10. Immunity to sexual stages of human malaria parasites: immune modulation during natural infections, antigenic determinants, and the induction of transmission-blocking immunity.
Targett G
Scand J Infect Dis Suppl; 1990; 76():79-88. PubMed ID: 1714627
[TBL] [Abstract][Full Text] [Related]
11. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.
Kaslow DC; Quakyi IA; Syin C; Raum MG; Keister DB; Coligan JE; McCutchan TF; Miller LH
Nature; 1988 May; 333(6168):74-6. PubMed ID: 3283563
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
13. Progress on vaccines against parasites.
Engers HD; Bergquist R; Modabber F
Dev Biol Stand; 1996; 87():73-84. PubMed ID: 8854004
[TBL] [Abstract][Full Text] [Related]
14. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials.
Nardin E; Zavala F; Nussenzweig V; Nussenzweig RS
Parassitologia; 1999 Sep; 41(1-3):397-402. PubMed ID: 10697892
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism in Plasmodium falciparum vaccine candidate antigens.
Mahajan RC; Farooq U; Dubey ML; Malla N
Indian J Pathol Microbiol; 2005 Oct; 48(4):429-38. PubMed ID: 16366089
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
17. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
[TBL] [Abstract][Full Text] [Related]
18. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
Sharma B
In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
[TBL] [Abstract][Full Text] [Related]
19. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.
Innes EA; Vermeulen AN
Parasitology; 2006; 133 Suppl():S145-68. PubMed ID: 17274844
[TBL] [Abstract][Full Text] [Related]
20. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
Rainczuk A; Scorza T; Spithill TW; Smooker PM
Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
